A quantitative assessment model of T-cell immune function for predicting risks of infection and rejection during the early stage after liver transplantation

Clinical Transplantation

Volumn 27, Issue 5, 2013, Pages 666-672

  Li, Rui dong ^a   Sun, Zhen ^a   Dong, Jia yong ^a   Yin, Hao ^a   Guo, Wen yuan ^a   Fu, Zhi ren ^a   Wang, Zheng xin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immune function; Liver transplantation; Quantitative assessment model; T lymphocytes

Indexed keywords

ADENOSINE TRIPHOSPHATE; CEFEPIME; GANCICLOVIR; IMIDAZOLE; PNEUMOCANDIN DERIVATIVE; TEICOPLANIN;

ARTICLE; BACTERIAL INFECTION; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; GRAFT INFECTION; GRAFT REJECTION; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MYCOSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VIRUS INFECTION;

IMMUNE FUNCTION; LIVER TRANSPLANTATION; QUANTITATIVE ASSESSMENT MODEL; T LYMPHOCYTES;

ADENOSINE TRIPHOSPHATE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LIVER TRANSPLANTATION; MODELS, THEORETICAL; POSTOPERATIVE COMPLICATIONS; PROGNOSIS;

EID: 84884988846     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12187     Document Type: Article

References (23)

1. Zhang M, Yin F, Chen B et al. Pretransplant prediction of posttransplant survival for liver recipients with benign end-stage liver diseases: a nonlinear model. PLoS ONE 2012: 7: e31256.
2. Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009: 2009: 701464.
3. Israeli M, Klein T, Sredni B et al. ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl 2008: 14: 893.
4. Rovira P, Mascarell L, Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem 2000: 7: 673.
5. Kowalski R, Post D, Schneider MC et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003: 17: 77.
6. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006: 82: 663.
7. Israeli M, Yussim A, Mor E, Sredni B, Klein T. Preceding the rejection: in search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol 2007: 18: 7.
8. Gautam A, Morrissey PE, Brem AS et al. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Pediatr Transplant 2006: 10: 613.
9. Uemura T, Riley TR, Khan A et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin Transplant 2011: 25: E32.
10. Huskey J, Gralla J, Wiseman AC. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 2011: 6: 423.
11. Serban G, Whittaker V, Fan J et al. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. Hum Immunol 2009: 70: 882.
12. Millan O, Urtasun N, Brunet M. Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients. Transplant Rev (Orlando) 2009: 23: 120.
13. Sanchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011: 140: 51.
14. Tseng SY, Dustin ML. T-cell activation: a multidimensional signaling network. Curr Opin Cell Biol 2002: 14: 575.
15. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006: 6: 262.
16. Demetrics AJ, Batts KP, Dhillon AP et al. Banff schema for grading liver allograft rejection an international consensus document. Hepatology 1997: 25: 658.
17. Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis 2009: 16: 226.
18. Wieland E, Olbricht CJ, Susal C et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010: 32: 560.
19. Meier-Kriesche H, Ojo AO, Arndorfer JA et al. Need for individualized immunosuppression in elderly renal transplant recipients. Transplant Proc 2001: 33: 1190.
20. Kim PS, Levy D, Lee PP. Modeling and simulation of the immune system as a self-regulating network. Methods Enzymol 2009: 467: 79.
21. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers 2011: 3: 3856.
22. Partridge FA, Gravato-Nobre MJ, Hodgkin J. Signal transduction pathways that function in both development and innate immunity. Dev Dyn 2010: 239: 1330.
23. Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008: 27: 990.